Icotrokinra Holds Up at Two Years in Plaque Psoriasis
Johnson & Johnson reports robust two-year data for ICOTYDE (icotrokinra) in plaque psoriasis across adults and adolescents, positioning the oral IL-23-targeting candidate as a durability story.
Topic
Plaque Psoriasis
Topic
Plaque Psoriasis
Setting Realistic Treatment Goals in Localized Plaque Psoriasis
Plaque psoriasis covers under 10% of the body in most patients. A Dermatology Times feature re-examines how clinicians set realis…
Lilly Reports Taltz-Zepbound Combo Beats Taltz Alone in Psoriasis Study
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are stil…
Icotrokinra Sustains High-Impact Psoriasis Site Clearance Through 2 Years
Phase 3 ICONIC-TOTAL data show oral icotrokinra achieved IGA 0/1 in 70% of psoriasis patients at Week 112, with 89% genital clear…
Phase 2 Trial Tests High-Induction Risankizumab in Plaque Psoriasis
A randomized phase 2 trial in Nature tests high-induction dosing of risankizumab in moderate-to-severe plaque psoriasis, probing…
Icotrokinra Holds Skin Clearance at High-Impact Psoriasis Sites at 2 Years
Icotrokinra sustained skin clearance at high-impact psoriasis sites through 2 years, per Dermatology Times. The milestone extends…
EADV 2026 Late-Stage Readouts: Coverage Pending Full Source
Clinical Trials Arena ran a headline on EADV 2026 late-stage readouts, but no article body was retrievable, so Derm Field cannot…
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…
EMA Backs First Oral IL-23 Receptor Agent for Plaque Psoriasis
The EMA's CHMP has adopted a positive opinion for the first oral IL-23 receptor-targeted therapy for plaque psoriasis, setting up…
Ascletis Reports Positive 28-Day U.S. Proof-of-Concept Results for Oral IL-17A Inhibitor ASC50
Ascletis reports positive 28-day U.S. proof-of-concept results for ASC50, a first-in-class oral small molecule IL-17A inhibitor f…